Sanofi has unveiled the global health brand, Impact, to make available standard of care treatments for non-profit supply to at-risk populations in low-income countries.
Through the Impact brand, which comprises insulin, glibenclamide and oxaliplatin among others, the company will supply its 30 medicines in 40 lower-income countries in the world.
Go deeper with GlobalData
The therapies cover a broad range of treatment areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer and are regarded essential by the World Health Organization.
In addition, Sanofi has set up an Impact fund that will aid startup firms as well as other innovators to offer scalable solutions for sustainable healthcare in underserved areas.
By offering inclusive businesses financing and technical help, the fund will complement the mission of GHU in using worldwide, regional and local investment to back the training of healthcare specialists and assist communities to manage sustainable care systems.
Sanofi Global Health Unit head Jon Fairest said: “The launch of the Impact brand and our Impact Fund are our latest steps to make our medicines available and to help bring quality, sustainable healthcare to people in the world’s poorest countries.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“But we know that we cannot do this alone, and so we are building partnerships at global, regional and local levels that will help to improve and establish health systems to reach our goal of a healthier, more resilient world.”
The introduction of the Impact brand is one of the steps adopted since the formation of Sanofi Global Health last year.
A non-profit unit within Sanofi, Sanofi Global Health aims to enhance access to healthcare by supplying therapies and strengthening regional healthcare systems in low-income countries.
In March this year, Sanofi signed an exclusive global partnership agreement with IGM Biosciences for the creation, development, production, and commercialisation of immunoglobulin M (IgM) antibody agonists for oncology, immunology, and inflammation targets.
